Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers的股价近期大幅下跌。上周五，在美国食品药品监督管理局（FDA）宣布司美格鲁肽注射产品的短缺问题已解决后，公司股价暴跌26%。去年五月，Hims & ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

智通财经APP获悉，远程医疗公司Hims & Hers ...

Despite a top-line fourth quarter beat and better-than-expected first quarter outlook, shares of Hims & Hers Health dropped, ...

During Monday’s regular session, shares of key tech companies dragged the S&P 500 and the Nasdaq Composite into negative ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

The online education company has tapped Goldman Sachs as it studies options such as going private or getting acquired.

Hims & Hers Health Inc.四季度EPS为0.11美元，2023年同期0.01美元。 四季度营收4.811亿美元，分析师预期4.704亿美元。 四季度净订单281万，分析师预期290万。 四季度平均订单价值168美元，分析师预期157.50美元。 四季度运营开支3.509亿美元，同比增长72%。 预计2025年营收23.0亿-24.0亿美元，分析师预期20.9亿美元。 预计一季度 ...